Mgr. Radek JORDA, Ph.D.
Telefon:
585634854
E-mail:
Pracoviště:
Katedra experimentální biologie
Org. jednotka:
Přírodovědecká fakulta
Adresa:
Šlechtitelů 27 A (hlavní budova)
Místnost:
3.23
Pracovní zařazení:
věd. prac. ob. biologických
VYBRANÉ PUBLIKACE
Peřina M., Kiss MA., Mótyán G., Szczyrbová E., Eliáš M., Študent V., Kurfürstová D., Kovalová M., Mada L., Bouchal J., Jorda R.
A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2023.
(ČLÁNEK)
ČLÁNEK
Maláriková D., Jorda R., Kupcová K., Kryštof V., Strnad M., Klener P.
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Experimental Hematology and Oncology.
2024.
Moradi M., Mousavi A., Řezníčková E., Peřina M., Vojáčková V., Jorda R., Grúz J., Kryštof V., Foroumadi A.
Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2024.
Delgado T., Veselá D., Dostálová H., Kryštof V., Vojáčková V., Jorda R., Strnad M., Salas CO.
New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs.
Pharmaceutics.
2024.
Moreira TM., Manuel DM., Rosa J., Vojáčková V., Jorda R., Nuno MX.
Synthesis and Antiproliferative Evaluation of D-Glucuronamide-Based Nucleosides and (Triazolyl)methyl Amide-Linked Pseudodisaccharide Nucleosides.
ChemMedChem.
2024.
Peřina M., Börzsei R., Ágoston H., Vojáčková V., Jorda R.
Synthesis and estrogenic activity of BODIPY-labeled estradiol conjugates.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES.
2024.
Kovalová M., Baraka JP., Mik V., Jorda R., Kryštof V.
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
EXPERT OPINION ON THERAPEUTIC PATENTS.
2023.
Dostálová H., Jorda R., Řezníčková E., Kryštof V.
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines.
INVESTIGATIONAL NEW DRUGS.
2023.
Kiss MA., Peřina M., Bereczki L., Bělíček J., Jorda R.
Dihydrotestosterone-based A-ring-fused pyridines: Microwave-assisted synthesis and biological evaluation in prostate cancer cells compared to structurally related quinolines.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY.
2023.
Kovalová M., Havlíček L., Djukic S., Peřina M., Pospíšil T., Řezníčková E., Jorda R., Kryštof V.
Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
BIOMEDICINE & PHARMACOTHERAPY.
2023.
Břehová P., Řezníčková E., Škach K., Jorda R., Vojáčková V., Kovalová M., Kinnertová M., Gucký T., Kryštof V.
Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping.
JOURNAL OF MEDICINAL CHEMISTRY.
2023.
Gonzalez G., Kvasnica M., Svrčková K., Peřina M., Jorda R.
Ring-fused 3β-acetoxyandrost-5-enes as novel neuroprotective agents with cholinesterase inhibitory properties.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY.
2023.
Peřina M., Kiss A., Mernyák E., Mada L., Jorda R.
Synthesis of hydrocortisone esters targeting androgen and glucocorticoid receptors in prostate cancer in vitro.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY.
2023.
Bertrand J., Dostálová H., Kryštof V., Jorda R.
Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.
Pharmaceutics.
2022.
Rudovich AS., Peřina M., Krech AV., Kvasnica M., Mada L., Jorda R.
Synthesis and Biological Evaluation of New Isoxazolyl Steroids as Anti-Prostate Cancer Agents.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2022.
Fortuna A., Gonçalves-Pereira R., Costa PJ., Jorda R., Vojáčková V., Gonzalez G.
Synthesis and Exploitation of the Biological Profile of Novel Guanidino Xylofuranose Derivatives.
ChemMedChem.
2022.
Tomanová M., Kozlanská K., Jorda R., Jedinák L., Havlíková T., Řezníčková E., Peřina M., Klener P., Dolníková A., Cankař P., Kryštof V.
Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2022.
Toman D., Jorda R., Ajani H., Kryštof V., Cankař P.
Synthesis of 4-styrylpyrazoles and Evaluation of their Inhibitory Effects on Cyclin-dependent Kinases.
Medicinal Chemistry.
2022.
Jorda R., Havlíček L., Peřina M., Vojáčková V., Pospíšil T., Grúz J., Strnad M., Kryštof V.
3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders.
JOURNAL OF MEDICINAL CHEMISTRY.
2022.
Hendrychová D., Jorda R., Kryštof V.
How selective are clinical CDK4/6 inhibitors?
MEDICINAL RESEARCH REVIEWS.
2021.
Jansa J., Jorda R., Škerlová J., Peřina M., Řezníčková E., Heger T., Gucký T., Kryštof V.
Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2021.
Jorda R., Molitorová V., Vojáčková V., Řezníčková E., Kryštof V.
Pseudopeptides with aldehyde or vinylsulfone warheads: Synthesis and antiproteasomal activity.
BIOORGANIC CHEMISTRY.
2021.
Kiss MA., Peřina M., Bazgier V., Jorda R.
Synthesis of dihydrotestosterone derivatives modified in the A-ring with (hetero)arylidene, pyrazolo[1,5-a]pyrimidine and triazolo[1,5-a] pyrimidine moieties and their targeting of the androgen receptor in prostate cancer.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY.
2021.
Kiełczewska U., Jorda R., Gonzalez G.
The synthesis and cholinesterase inhibitory activities of solasodine analogues with seven-membered F ring.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY.
2021.
Krajčovičová S., Jorda R., Vanda D., Soural M., Kryštof V.
1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2021.
Dayal N., Řezníčková E., Hernandez DE., Peřina M., Vojáčková V., Kryštof V., Jorda R.
3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo.
JOURNAL OF MEDICINAL CHEMISTRY.
2021.
Štětková M., Growková K., Fojtík P., Jorda R., Kryštof V.
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Cell Death & Disease.
2020.
Bertrand J., Dostálová H., Kryštof V., Jorda R.
New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.
BIOORGANIC CHEMISTRY.
2020.
Jorda R., Magar P., Hendrychová D., Kryštof V.
Novel modified leucine and phenylalanine dipeptides modulate viability and attachment of cancer cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2020.
Köprülüoglu C., Dejmek M., Šála M., Ajani HB., Jorda R., Kryštof V., Hobza P.
Optimization of norbornyl-based carbocyclic nucleoside analogs as cyclin-dependent kinase 2 inhibitors.
JOURNAL OF MOLECULAR RECOGNITION.
2020.
Salas CO., Zarate AM., Kryštof V., Hendrychová D., Jorda R.
Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2020.
Jorda R., Krajčovičová S., Králová P., Soural M., Kryštof V.
Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2020.
Řezníčková E., Gucký T., Kováčová V., Ajani H., Jorda R., Kryštof V.
Activity of 2,6,9-trisubstituted purines as potent PDGFR alpha kinase inhibitors with antileukaemic activity.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Xavier NM., Goncalves-Pereira R., Jorda R., Hendrychová D., Oliveira MC.
Novel dodecyl-containing azido and glucuronamide-based nucleosides exhibiting anticancer potential.
PURE AND APPLIED CHEMISTRY.
2019.
Krajčovičová S., Jorda R., Hendrychová D., Kryštof V., Soural M.
Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC).
CHEMICAL COMMUNICATIONS.
2019.
Jorda R., Řezníčková E., Kielczewska U., Bazgier V., Berka K., Rárová L.
Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Jorda R., Lopes SMM., Řezníčková E.
Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Abo-Ashour MF., Eldehna WM., Nocentini A., Kryštof V., Jorda R.
3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Jorda R., Havlíček L., Šturc A., Peřina M., Pospíšil T., Široká J., Urbánek L., Strnad M., Kryštof V.
3,5,7-Substituted Pyrazolo[4,3-d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Gucký T., Řezníčková E., Radošová Muchová T., Jorda R., Klejová Z., Malínková V., Berka K., Bazgier V., Ajani HB., Lepšík M., Divoký V., Kryštof V.
Discovery of N-2-(4-Amino-cyclohexyl)-9-cyclopentyl-N-6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations.
JOURNAL OF MEDICINAL CHEMISTRY.
2018.
Jorda R., Hendrychová D., Voller J., Řezníčková E., Gucký T., Kryštof V.
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
JOURNAL OF MEDICINAL CHEMISTRY.
2018.
Jorda R., Bučková Z., Řezníčková E., Bouchal J., Kryštof V.
Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81.
Biochimica et Biophysica Acta - Molecular Cell Research.
2018.
Milisiunaite V., Arbaciauskiene E., Řezníčková E., Jorda R., Malínková V., Žukauskaite A., Holzer W., Sackus A., Kryštof V.
Synthesis and anti-mitotic activity of 2,4-or 2,6-disubstituted- and 2,4,6-trisubstituted-2H-pyrazolo[4,3-c]pyridines.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2018.
Řezníčková E., Tenora L., Pospíšilová P., Galeta J., Jorda R., Berka K., Majer P., Potáček M., Kryštof V.
ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethy1-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
European Journal of Medicinal Chemistry.
2017.
Jorda R., Lopes SMM., Řezníčková E., Kryštof V., Pinho e. Melo TMVD.
Biological Evaluation of Dipyrromethanes in Cancer Cell Lines: Antiproliferative and Pro-apoptotic Properties.
ChemMedChem.
2017.
Hylsová M., Carbain B., Fanfrlík J., Musilová L., Haldar S., Koepruelueoglu C., Ajani H., Brahmkshatriya PS., Jorda R., Kryštof V., Hobza P., Echalier A., Paruch K., Lepšík M.
Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
European Journal of Medicinal Chemistry.
2017.
Xavier NM., Porcheron A., Batista D., Jorda R., Řezníčková E., Kryštof V., Oliveira CM.
Exploitation of new structurally diverse D-glucuronamide-containing N-glycosyl compounds: synthesis and anticancer potential.
Organic & Biomolecular Chemistry.
2017.
Cavallaro V., Řezníčková E., Jorda R., Alza NP., Murray AP., Kryštof V.
Semisynthetic Esters of 17-Hydroxycativic Acid with in Vitro Cytotoxic Activity against Leukemia Cell Lines.
Biological and Pharmaceutical Bulletin.
2017.
Nekardová M., Vymětalová L., Khirsariya P., Kováčová S., Hylsová M., Jorda R., Kryštof V., Fanfrlík J., Hobza P., Paruch K.
Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.
ChemPhysChem.
2017.
Dušek J., Imramovský A., Pauk K., Jorda R., Řezníčková E., Kryštof V.
Synthesis and Antiproliferative Activities of Novel O-Benzyl Salicylamide Derivatives.
Letters in Drug Design and Discovery.
2017.
Xavier NM., Goncalves-Pereira R., Jorda R., Řezníčková E., Kryštof V., Oliveira CM.
Synthesis and antiproliferative evaluation of novel azido nucleosides and their phosphoramidate derivatives.
Pure and Applied Chemistry.
2017.
Jorda R., Dušek J., Řezníčková E., Pauk K., Magar PP., Imramovský A., Kryštof V.
Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
European Journal of Medicinal Chemistry.
2017.
Malínková V., Řezníčková E., Jorda R., Gucký T., Kryštof V.
Trisubstituted purine inhibitors of PDGFR alpha and their antileukemic activity in the human eosinophilic cell line EOL-1.
Bioorganic & Medicinal Chemistry.
2017.
Zhang S., Ulrich M., Gromnicka A., Havlíček L., Kryštof V., Jorda R., Strnad M., Vollmar AM., Zahler S.
Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.
British Journal of Pharmacology.
2016.
Baltus CB., Jorda R., Marot C., Berka K., Bazgier V., Kryštof V., Prie G., Viaud-Massuard M.
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
European Journal of Medicinal Chemistry.
2016.
Vymětalová L., Havlíček L., Šturc A., Bučková Z., Jorda R., Pospíšil T., Strnad M., Kryštof V.
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
European Journal of Medicinal Chemistry.
2016.
Řezníčková E., Weitensteiner S., Havlíček L., Jorda R., Gucký T., Berka K., Bazgier V., Zahler S., Kryštof V., Strnad M.
Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Chemical Biology and Drug Design.
2015.
Jorda R., Schütznerová E., Cankař P., Brychtová V., Navrátilová J., Kryštof V.
Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Bioorganic & Medicinal Chemistry.
2015.
Xavier NM., Lucas SD., Jorda R., Schwarz S., Loesche A., Csuk R., Oliveira MC.
Synthesis and Evaluation of the Biological Profile of Novel Analogues of Nucleosides and of Potential Mimetics of Sugar Phosphates and Nucleotides.
Synlett.
2015.
Vanda D., Jorda R., Lemrová B., Volná T., Kryštof V., Mcmaster C., Soural M.
Synthesis of Novel N-9-Substituted Purine Derivatives from Polymer Supported alpha-Amino Acids.
ACS Combinatorial Science.
2015.
Vanda D., Jorda R., Lemrová B., Volná T., Kryštof V., Mcmaster C., Soural M.
Synthesis of novel N9-substituted purine derivatives from polymer supported α-amino acids.
ACS Combinatorial Science.
2015.
Řezníčková E., Popa A., Gucký T., Zatloukal M., Havlíček L., Bazgier V., Berka K., Jorda R., Popa I., Nasereddin A., Jaffe CL., Kryštof V., Strnad M.
2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.
Bioorganic & Medicinal Chemistry Letters.
2015.
Jorda R., Navrátilová J., Hušková Z., Schütznerová E., Cankař P., Strnad M., Kryštof V.
Arylazopyrazole AAP1742 Inhibits CDKs and Induces Apoptosis in Multiple Myeloma Cells via Mcl-1 Downregulation.
Chemical Biology and Drug Design.
2014.
Gucký T., Jorda R., Zatloukal M., Bazgier V., Berka K., Řezníčková E., Béres T., Strnad M., Kryštof V.
A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors.
Journal of Medicinal Chemistry.
2013.
Haider C., Grubinger M., Řezníčková E., Weiss T., Rotheneder H., Miklos W., Berger W., Jorda R., Zatloukal M., Gucký T., Strnad M., Kryštof V., Mikulits W.
Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance.
Molecular Cancer Therapeutics.
2013.
Imramovský A., Jorda R., Pauk K., Řezníčková E., Dušek J., Hanušek J., Kryštof V.
Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines.
European Journal of Medicinal Chemistry.
2013.
Zatloukal M., Jorda R., Gucký T., Řezníčková E., Voller J., Pospíšil T., Malínková V., Adamcová H., Kryštof V., Strnad M.
Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
European Journal of Medicinal Chemistry.
2013.
Jorda R., Paruch K., Kryštof V.
Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres.
Current Pharmaceutical Design.
2012.
JORDA R., Sacerdoti-Sierra N., VOLLER J., HAVLÍČEK L., Kracalíková K., Nowicki M., Nasereddin A., KRYŠTOF V., STRNAD M., Walkinshaw M., Jaffe C.
Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines.
Bioorganic & Medicinal Chemistry Letters.
2011.
JORDA R., HAVLÍČEK L., McNae I., Walkinshaw M., VOLLER J., Šturc A., Navrátilová J., Kuzma M., MISTRÍK M., BÁRTEK J., STRNAD M., Kryštof V.
Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity.
Journal of Medicinal Chemistry.
2011.
KRYŠTOF V., RÁROVÁ L., Liebl J., Zahler S., JORDA R., VOLLER J., CANKAŘ P.
The selective P-TEFb inhibitor CAN508 targets angiogenesis.
European Journal of Medicinal Chemistry.
2011.
Frébortová J., Novák O., Frébort I., Jorda R.
Degradation of cytokinins by maize cytokinin dehydrogenase is mediated by free radicals generated by enzymatic oxidation of natural benzoxazinones.
Plant Journal.
2010.
Kryštof V., Chamrád I., Jorda R., Kohoutek J.
Pharmacological targeting of CDK9 in cardiac hypertrophy.
Medicinal Research Reviews.
2010.
Paprskářová M., Kryštof V., Jorda R., Džubák P., Hajdúch M., Wesierska-Gadek J., Strnad M.
Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Journal of Cellular Biochemistry.
2009.
Paprskářová M., Kryštof V., Jorda R., Džubák P., Hajdúch M., Wesierska-Gadek JA., Strnad M.
Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Journal of Cellular Biochemistry.
2009.
KAPITOLA V KNIZE
Veselá D., Řezníčková E., Mik V., Jorda R.
PROTACs of cyclin-dependent kinases.
Annual Reports in Medicinal Chemistry.
2024.
PATENT, UŽITNÝ VZOR, PRŮMYSLOVÝ VZOR
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V.
2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions.
2021.
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V.
2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions.
2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M.
5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-D]pyrimidines for treatment of lymphoma.
2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M.
5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-D]pyrimidines for treatment of lymphoma.
2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M.
5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů.
2020.
Gucký T., Řezníčková E., Jorda R., Divoký V., Kryštof V., Radošová Muchová T., Strnad M.
2,6-disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky.
2019.
Havlíček L., Šturc A., Kryštof V., Jorda R., Pospíšil T., Zahler S., Vollmar A., Strnad M.
5-substituted 7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo[4,3-D]pyrimidine derivatives, use thereof as medicaments and pharmaceutical compositions.
2019.
Havlíček L., Šturc A., Kryštof V., Jorda R., Pospíšil T., Zahler S., Vollmar A., Strnad M.
5-substituted 7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo4,3-D]pyrimidine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2018.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
ПРОИЗВОДНЫЕ 2-ЗАМЕЩЕННЫХ-6-БИАРИЛМЕТИЛАМИНО-9-ЦИКЛОПЕНТИЛ-9Н-ПУРИНОВ, ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ И ФАРМАЦЕВТИЧЕСКИХ СОСТАВОВ.
2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
N2-substituted-N6-(6-aryl-pyridine-3-ylmethyl)-9-cyclopentyl-9H-purine-2,6-diamine derivatives as tumor suppressor p53 activators for inhibiting angiogenesis and for treating cancer.
2017.
Zatloukal M., Kryštof V., Havlíček L., Popa I., Doležal K., Strnad M., Jorda R.
Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives.
2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-Substituované-6-biarylmethyalmino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující.
2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2017.
Strnad M., Mikulits W., Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Strnad M., Mikulits W.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Zatloukal M., Kryštof V., Havlíček L., Popa I., Doležal K., Strnad M., Jorda R.
Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives.
2013.
ZATLOUKAL M., KRYŠTOF V., Havlíček L., POPA I., DOLEŽAL K., STRNAD M., JORDA R.
Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující.
2011.
ABSTRAKT
Jorda R., Řezníčková E., Kryštof V., Havlíček L., Strnad M.
A novel pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases: antiproliferative and proapoptotic effects.
European Journal of Cancer. Supplement.
2010.
Řezníčková E., Jorda R., Kryštof V., Havlíček L., Strnad M.
A novel pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases: antiproliferative and proapoptotic effects.
European Journal of Cancer. Supplement.
2010.
Jorda R., Kryštof V., Havlíček L., Strnad M.
Biochemical and cellular effects of a novel cyclin-dependent kinase inhibitor.
European Journal of Cancer. Supplement.
2008.
Frébortová J., Novák O., Jorda R.
Role of benzoxazinones in the activation of maize cytokinin dehydrogenase.
Physiologia Plantarum.
2008.
Uživatel nepovolil zobrazení dat v Portále UP.